Clinical-stage biotechnology company ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS on Wednesday announced the execution of a definitive licensing agreement with Serum Institute of India Pvt. Ltd. for two novel blood-stage malaria vaccines, RH5.1 and R78C.
The agreement builds upon the previously announced term sheet and secures SII's rights to use ExpreS2ion's proprietary production platform, ExpreS2, to further develop, manufacture, and commercialise RH5.1 and R78C.
Under the terms, ExpreS2ion is entitled to upfront and milestone payments, aggregated amounting to low single-digit EUR millions, as well as royalties ranging from below 1% to mid-single digit percentages on future net sales. The collaboration strengthens the commitment of both parties to accelerate access to an innovative malaria vaccine with potential to significantly reduce disease burden worldwide.
Malaria remains a deadly parasitic disease with devastating impacts, particularly on vulnerable populations in low- and middle-income countries. In 2023, there were an estimated 263 million cases of malaria worldwide and approximately 597,000 deaths, with 76% of fatalities occurring in children under five in the African Region.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.